Skip to main content
Fig. 4 | BMC Medical Research Methodology

Fig. 4

From: Crude incidence in two-phase designs in the presence of competing risks

Fig. 4

Crude cumulative incidence of relapse in ALL data. Panel a reports the crude cumulative incidence estimate of relapse involving the bone marrow in patients with normal (estimate and confidence limits reported with solid lines) and deleted (dashed lines) GST-T1 gene. Panel b reports the crude cumulative incidence estimate of relapse in extramedullary sites in patients with normal (solid lines) and deleted (dashed lines) GST-T1 gene

Back to article page